---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-192874"
form_type: "8-K"
ticker: "CTMX"
cik: "0001501989"
company_name: "CytomX Therapeutics, Inc."
filed_at: "2022-07-13T23:59:59+00:00"
generated_at: "2026-06-24T15:52:47.335063+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CytomX cuts ~40% of staff, $10M restructuring charge; COO, CFO, CMO to depart

## Summary
- Workforce reduction of ~40% primarily in development and G&A; completion expected by Q4 2022.
- Estimated restructuring charges of ~$10M, mainly severance, recorded in Q3 and Q4 2022.
- Cash runway extended into 2025 as a result of the restructuring.
- President/COO Amy Peterson to leave effective Sept 12, 2022; CFO Carlos Campoy and CMO Alison Hannah effective Sept 30, 2022.
- Company to prioritize pre-clinical/early clinical pipeline with two INDs planned for 2023.

## SEC filing metadata
- accession: 0001193125-22-192874
- form_type: 8-K
- ticker: CTMX
- cik: 0001501989
- company_name: CytomX Therapeutics, Inc.
- filed_at: 2022-07-13T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.05, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501989/000119312522192874/0001193125-22-192874-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501989/000119312522192874/d267419d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-192874
- JSON: https://secwatch.observer/filing/0001193125-22-192874.json
- Plain text: https://secwatch.observer/filing/0001193125-22-192874.txt

## Key facts
- Executive change
  Carlos Campoy was terminated as SVP, Chief Financial Officer at CytomX Therapeutics, Inc..
  - Action: terminated
  - Role: SVP, Chief Financial Officer
  source text: the employment of Carlos Campoy, the Company’s SVP, Chief Financial Officer, and Alison Hannah, M.D., the Company’s SVP, Chief Medical Officer, is expected to terminate effective as of September 30, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501989/000119312522192874/0001193125-22-192874-index.htm
- Executive change
  Alison Hannah was terminated as SVP, Chief Medical Officer at CytomX Therapeutics, Inc..
  - Action: terminated
  - Role: SVP, Chief Medical Officer
  source text: the employment of Carlos Campoy, the Company’s SVP, Chief Financial Officer, and Alison Hannah, M.D., the Company’s SVP, Chief Medical Officer, is expected to terminate effective as of September 30, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501989/000119312522192874/0001193125-22-192874-index.htm
- Executive change
  Amy Peterson was terminated as President and Chief Operating Officer at CytomX Therapeutics, Inc..
  - Action: terminated
  - Role: President and Chief Operating Officer
  source text: the employment of Amy Peterson, M.D., the Company’s President and Chief Operating Officer, is expected to terminate effective September 12, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501989/000119312522192874/0001193125-22-192874-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.